美洲 · 区域市场 · Financial Post
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2…
在 Financial Post 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (financialpost.com)
